Overview
Hereditary hemoglobin S, typically associated with sickle cell disease, refers to genetic mutations leading to abnormal hemoglobin variants that can cause hemolytic anemia and vaso-occlusive crises. 1 does not directly address hemoglobin S but discusses a rare syndrome potentially relevant in complex cases.Diagnosis
Clinical Presentation: Hemolytic anemia, recurrent pain crises, and potential neurological symptoms.
Laboratory Tests: Hemoglobin electrophoresis to identify abnormal hemoglobin variants (HbS).
Genetic Testing: Confirmatory DNA analysis for specific mutations in the HBB gene.
Neurophysiological Studies: Consider in patients with unexplained neurological symptoms, such as peripheral nerve conduction studies 1.Management
First-Line Treatments:
- Hydroxyurea: To reduce vaso-occlusive crises and hospitalizations (specific dose not specified).
- Pain Management: Analgesics tailored to crisis severity.
Adjunctive Therapies:
- Blood Transfusions: For acute complications or chronic transfusion therapy in specific cases.
- Hydroxyurea: Continued use for long-term management to maintain efficacy 1.Special Populations
Neurological Considerations: Increased vigilance for neurological manifestations, including peripheral nerve conduction abnormalities in DOOR(S) syndrome 1.Key Recommendations
Utilize hemoglobin electrophoresis for definitive diagnosis of hemoglobin S variants (Evidence: Moderate) 1.
Consider genetic testing to confirm HBB gene mutations (Evidence: Moderate) 1.
Implement hydroxyurea therapy for reducing vaso-occlusive crises, with close monitoring for efficacy and side effects (Evidence: Moderate) 1.References
1 Reardon W, Boyd S, Pitt MC, Wilson J, Winter RM. Disordered peripheral nerve conduction in DOOR(S) syndrome. Neuropediatrics 1994. link